Oncology Cardiology / Cardiovascular Respiratory / COPD / Asthma Infectious Disease Gastroenterology Neurology Rheumatology Diabetes / Metabolic Mental Health / Psychiatry Women's Health Dermatology Men's Health Rare Diseases
Clinical Trial ● Currently Recruiting NCT02834884

SPECTA: Screening Cancer Patients for Efficient Clinical Trial Access

SPECTA: Screening Cancer Patients for Efficient Clinical Trial Access — Recruiting • Oncology • NCT02834884.

📅 17 Apr 2026 ⏱ 1 min read
Currently Recruiting
This trial is actively seeking participants in the UK. Discuss eligibility with your patient before referring.
Status
Currently Recruiting
NCT ID
NCT02834884
Sponsor
European Organisation for Research and Treatment of Cancer - EORTC
Start
2017-05-03
ClinicaliQ Trial Snapshot
  • SPECTA: Screening Cancer Patients for Efficient Clinical Trial Access — Recruiting • Oncology • NCT02834884.
  • What is being tested: SPECTA is a standardized biobank platform collecting high-quality annotated biological samples, imaging data, operative records, and patient-reported outcomes from cancer patients to enable biomarker discovery and support translational research across multiple cancer types.
  • Patient eligibility overview: The platform recruits cancer patients across various tumour types and disease stages, with structured collection of clinicopathological data, environmental assessments, and validated questionnaires to create a comprehensive, quality-assured research resource.
Use This Page For
  • Quick orientation before opening the registry record.
  • Checking recruitment status, phase and sponsor at a glance.
  • Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying

SPECTA is a quality assured platform for collecting clinicopathologically annotated biological material, imaging data, operative images, environmental assessment, questionnaires as well as patient-reported outcomes from cancer patients to support biospecimen-based translational research and clinical cancer research, including biomarker discovery to improve the understanding of tumor biology and cancer patients care.

Eligibility Snapshot
  • * Patients with pathologically confirmed selected tumor types (at site or centrally); * Mandatory availability of adequate human biological material (HBM); * Centrally performed confirmation of HBM adequacy in terms of quality and quantity for SPECTA downstream project requirements; * Age ≥ 12 years; * Absence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; * Written informed consent according to applicable legal and ethical requirements;

Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.

Full Trial Details
View this trial on the source registry
Eligibility criteria, protocol, and results when available
View Trial ↗
Share: Twitter/X LinkedIn
Related

Related Clinical Intelligence

Guidelines, Drug Science, safety briefs and education connected to this trial area.

Clinical Brief
Ultrasound delays putting pregnant women and cancer patients at risk, sonographers say
Oncology · BBC Health · 28 Mar 2026
Ultrasound service capacity is insufficient due to inadequate sonographer training, creating delays that compromise care for pregnant women and cancer patients requiring…
View brief →
Clinical Brief
Breast cancer type study ‘critically under-funded’
Oncology · BBC Health · 22 Apr 2026
Lobular breast cancer remains under-researched and under-funded compared to other breast cancer types, limiting evidence for optimal clinical management Patient advocates are…
View brief →
Guideline
Nivolumab with chemotherapy for untreated unresectable or metastatic urothelial cancer (terminated appraisal)
Oncology · 17 Mar 2026
I appreciate your request, but I need to be transparent: the content provided only includes the title, metadata, and editorial notes -…
View guideline →
Guideline
Zanidatamab for treating HER2-positive advanced biliary tract cancer after 1 or more lines of systemic treatment
Oncology · 07 May 2026
Zanidatamab is recommended by NICE as an option for HER2-positive advanced biliary tract cancer only after 1 or more prior lines of…
View guideline →
Guideline
Bladder Cancer: Diagnosis and Management (NICE NG2)
Oncology · 27 Mar 2026
Blue light cystoscopy with hexaminolevinate improves detection of recurrent bladder tumours compared to white light cystoscopy alone, particularly for carcinoma in situ.…
View guideline →
Clinical Brief
Women attending first NHS mammogram hits 10-year high as thousands more cancers found
Oncology · NHS England · 19 Feb 2026
Hundreds of thousands more women attended NHS breast screening last year and thousands more cancers were diagnosed early in England. New figures…
View brief →